

Stanford



Sumit Shah

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic E

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 736-7379

Bio

BIO

Dr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.

CLINICAL FOCUS

- Oncology
- Prostate Cancer
- Kidney Cancer
- Bladder Cancer
- Testicular Cancer/Germ Cell Tumor
- Immunotherapy

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- US Fulbright Scholar, South Korea (2005)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship CA
- Board Certification: Oncology, American Board of Internal Medicine (2017)

- Board Certification: Internal Medicine, American Board of Internal Medicine (2013)
- Residency: UCSF Internal Medicine Residency (2013) CA
- Medical Education: Stanford University School of Medicine Registrar (2010) CA
- Fellowship, Stanford University Hospital , Oncology/Hematology (2017)
- Residency, University of California, San Francisco (UCSF) , Internal Medicine (2013)
- MPH, Harvard School of Public Health (2010)
- MD, Stanford School of Medicine (2010)
- BSE, Duke University (2004)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Publications

PUBLICATIONS

- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019; JCO1802018
- **Consolidative Radiotherapy in Metastatic Urothelial Cancer.** *Clinical genitourinary cancer*
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., Srinivas, S.
2017
- **Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study** *LANCET ONCOLOGY*
Changa, N., Xie, W., Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., Balakrishnan, A., Bowman, I., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, et al
2019; 20 (4): 581–90
- **Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B. I., Gomez, S. L., Cheng, I.
2018; 16 (11): 1353–60
- **In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study** *BLOOD*
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., Tibshirani, R. J., Advani, R. H., Lingala, et al
2012; 119 (2): 355-363